The overexpression of the erbB-2 (HER-2, neu) gene has attracted signi
ficant interest as a molecular target for the rational design of cance
r therapies. This review examines the design and preclinical testing p
hase for one such experimental therapy, recombinant toxins targeted to
the erbB-2 protein, termed e23(Fv)PEs.